Christine B. Hunter, R.N., C.C.R.C.

- **Instructor of Neurology**

Clinical Service Area

Neurology

Graduate School

R.N., Houston Community College, Texas

Clinical Interests

Movement disorders including Parkinson's disease, essential tremor, dystonia, Tourette's syndrome and Huntington's disease

Research Interests

Experimental therapeutics and genetics of movement disorders

Contact Information

Christine B. Hunter, R.N., C.C.R.C.
Department of Neurology
Baylor College of Medicine
One Baylor Plaza, MS NB302
Houston, Texas 77030

Tel: 713-798-3951
Fax: 713-798-6808
Email: chunter@bcm.edu

Journal Publications

1. Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, et al. A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit. JAMA Neurol. 2014;:. [View journal article]
2. Pulliam CL, Eichenseer SR, Goetz CG, Waln O, Hunter CB, Jankovic J, et al. Continuous in-home monitoring of essential tremor. Parkinsonism Relat Disord. 2014;20(1):37-40. [View journal article]
3. Mehanna R, Hunter C, Davidson A, Jimenez-Shahed J, Jankovic J. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013;28(2):210-5. [View journal article]
4. Shen V, Clarence-Smith K, Hunter C, Jankovic J. Safety and Efficacy of Tetrabenazine and Use of Concomitant Medications During Long-Term, Open-Label Treatment of Chorea Associated with Huntington's and Other Diseases. Tremor Other Hyperkinet Mov (N Y). 2013;3:. [View journal article]
5. Ondo WG, Hunter C, Ferrara JM, Mostile G. Apomorphine injections: predictors of initial common adverse events and long term tolerability. Parkinsonism Relat Disord. 2012;18(5):619-22. [View journal article]
6. Ondo WG, Kenney C, Sullivan K, Davidson A, Hunter C, Jahan I, et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology. 2012;78(21):1650-4. [View journal article]
7. Ondo WG, Hunter C, Isaacson SH, Silver DE, Stewart RM, Tetrud JW, et al. Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease. Parkinsonism Relat Disord. 2011;17(2):117-8. [View journal article]

8. Ferrara J, Diamond A, Hunter C, Davidson A, Almaguer M, Jankovic J. Impact of STN-DBS on life and health satisfaction in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2010;81(3):315-9. [View journal article]
9. Quaid KA, Swenson MM, Sims SL, Harrison JM, Moskowitz C, Stepanov N, et al. What were you thinking?: individuals at risk for Huntington Disease talk about having children. J Genet Couns. 2010;19(6):606-17. [View journal article]
10. Paulsen JS, Nopoulos PC, Aylward E, Ross CA, Johnson H, Magnotta VA, et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull. 2009;82(3-4):201-7. [View journal article]
11. Frank S, Ondo W, Fahn S, Hunter C, Oakes D, Plumb S, et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008;31(3):127-33. [View journal article]
12. Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol. 2008;48(3):379-84. [View journal article]
13. Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79(8):874-80. [View journal article]
14. Deng H, Le WD, Hunter CB, Mejia N, Xie WJ, Jankovic J. A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations. Arch Neurol. 2007;64(3):421-4. [View journal article]
15. Ishihara L, Gibson RA, Warren L, Amouri R, Lyons K, Wielinski C, et al. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord. 2007;22(1):55-61. [View journal article]
16. Kenney C, Diamond A, Mejia N, Davidson A, Hunter C, Jankovic J. Distinguishing psychogenic and essential tremor. J Neurol Sci. 2007;263(1-2):94-9. [View journal article]
17. Kenney C, Hunter C, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord. 2007;22(1):10-3. [View journal article]
18. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007;22(2):193-7. [View journal article]
19. Kenney C, Simpson R, Hunter C, Ondo W, Almaguer M, Davidson A, et al. Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. J Neurosurg. 2007;106(4):621-5. [View journal article]
20. Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat Disord. 2007;13(7):453-4. [View journal article]
21. Tan EK, Lee J, Hunter C, Shinawi L, Fook-Chong S, Jankovic J. Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population. J Neurol Sci. 2007;252(2):113-20. [View journal article]
22. Deng H, Le W, Guo Y, Hunter CB, Xie W, Huang M, et al. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol Sci. 2006;251(1-2):102-6. [View journal article]
23. Deng H, Le WD, Hunter CB, Ondo WG, Guo Y, Xie WJ, et al. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch Neurol. 2006;63(2):273-7. [View journal article]
24. Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006;67(12):2233-5. [View journal article]
25. Kenney C, Hunter C, Mejia N, Jankovic J. Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol. 2006;29(5):259-64. [View journal article]
26. Deng H, Le W, Guo Y, Hunter CB, Xie W, Jankovic J. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol. 2005;57(6):933-4. [View journal article]
27. Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology. 2004;62(1):37-40. [View journal article]
28. Ondo WG, Hunter C. Flumazenil, a GABA antagonist, may improve features of Parkinson's disease. Mov Disord. 2003;18(6):683-5. [View journal article]
29. Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord. 2002;8(4):271-6. [View journal article]
30. Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002;17(5):1031-5. [View journal article]

31. Xu PY, Liang R, Jankovic J, Hunter C, Zeng YX, Ashizawa T, et al. Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology. 2002;58(6):881-4. [View journal article]
32. Ondo W, Hunter C, Vuong KD, Schwartz K, Jankovic J. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord. 2000;15(4):678-82. [View journal article]
33. Ondo WG, Hunter C, Vuong KD, Jankovic J. The pharmacokinetic and clinical effects of tolcapone on a single dose of sublingual apomorphine in Parkinson's disease. Parkinsonism Relat Disord. 2000;6(4):237-240. [View journal article]
34. Ondo W, Hunter C, Almaguer M, Gancher S, Jankovic J. Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease. Clin Neuropharmacol. 1999;22(1):1-4. [View journal article]
35. Ondo W, Hunter C, Almaguer M, Jankovic J. A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease. Mov Disord. 1999;14(4):664-8. [View journal article]

Book Chapters and Other Publications

1. Jankovic J, Hunter C. Psychogenic parkinsonism. In: Hallett M, Cloninger CR, Fahn S, Halligan P, Jankovic J, Lang AE, Voon V, editors. Psychogenic movement disorders and other conversion disorders. Cambridge, UK: 2011. p. 14-19.

Poster and Platform Presentations

1. Pulliam CL, Eichenseer S, Goetz C, Waln O, Hunter C, Jankovic J, et al. Continuous home monitoring of essential tremor using motion sensors. Neurology. 2013;80(Meeting Abstracts 1):P05.035.
2. Baizabal Carvallo JF, Suresh K, Hunter C, Jankovic J. Flu-like and systemic symptoms following treatment with botulinum toxins. Mov Disord. 2012;27(Suppl 1):S422. [View poster]
3. Mehanna R, Hunter C, Davidson A, Ondo W, Jimenez-Shahed J, Jankovic J. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2012;27(Suppl 1):S457. [View poster]
4. Shen V, Clarence-Smith K, Hunter C, Jankovic J. Concomitant use of antidepressants and neuroleptics with tetrabenazine during treatment of Huntington's disease. Mov Disord. 2012;27(Suppl 1):S59-60. [View poster]
5. Shen V, Clarence-Smith K, Hunter C, Jankovic J. Long-term safety and efficacy of tetrabenazine in the treatment of chorea associated with Huntington's disease. Mov Disord. 2012;27(Suppl 1):S60. [View poster]
6. Shen V, Clarence-Smith K, Hunter C, Jankovic J. Tetrabenazine for moderate vs. severe/disabling chorea associated with Huntington's disease. Mov Disord. 2012;27(Suppl 1):S60. [View poster]
7. York MK, Marsh L, Jimenez-Shahed J, Okun M, Moro E, Hunter C, et al. Parkinson's Study Group Neurosurgical Working Group (PSG-NSWG) deep brain stimulation (DBS) non-motor symptoms (NMS) survey: Real world pre-operative practice patterns. Mov Disord. 2012;27(Suppl 1):S172. [Previously Presented] [View poster]
8. York MK, Marsh L, Jimenez-Shahed J, Okun M, Moro E, Hunter C, et al. Parkinson's Study Group Neurosurgical Working Group (PSG-NSWG) deep brain stimulation (DBS) non-motor symptoms (NMS) survey: Real world pre-operative practice patterns. Mov Disord. 2012;27(4):e12. [View poster]
9. Clarence-Smith K, Shen V, Hunter C, Jankovic J. Concomitant use of antidepressants and neuroleptics with tetrabenazine during treatment of Huntington's disease (HD). Neurology. 2012;78(Meeting Abstracts 1):P06.039. [View poster]
10. Meunier C, Jennings D, Hunter C, Sherer T. Fox Trial Finder: An innovative web-based trial matching tool to facilitate clinical trial recruitment. Neurology. 2012;78(Meeting Abstracts 1):P02.241.
11. Ondo W, Hashem V, Hunter C, Simmons J. Onabotulinum toxin-A injections for nocturnal bruxism: A parallel, double blind, placebo controlled polysomnographic study. Neurology. 2012;78(Meeting Abstracts 1):P05.006.
12. Shen V, Clarence-Smith K, Hunter C, Jankovic J. Long-term safety and efficacy of tetrabenazine in the treatment of chorea associated with Huntington's disease. Neurology. 2012;78(Meeting Abstracts 1):P06.034. [View poster]
13. Shen V, Clarence-Smith K, Hunter C, Jankovic J. Tetrabenazine for moderate vs. severe/disabling chorea associated with Huntington's disease (HD). Neurology. 2012;78(Meeting Abstracts 1):P06.032.

[View poster]

14. Waln O, Jimenez Shahed J, Juliet Wendt, York M, Baizabal Carvallo J, Mehanna R, et al. Diagnostic reliability of DaT scan in movement disorders. Neurology. 2012;78(Meeting Abstracts 1):P03.125. [View poster]
15. Ondo WG, Daleiden A, Davidson A, Hunter C, Jahan I, Miller A, et al. Lubiprostone for constipation in Parkinson's disease, a multicenter, placebo controlled parallel trial. Mov Disord. 2011;26 Suppl 2:S137. [View poster]
16. Palao AM, Hunter CB, Jankovic J. Patients' perspective of tetrabenazine two years after FDA approval. Mov Disord. 2011;26 Suppl 2:S259. [View poster]
17. Davidson AL, Hunter C, Jankovic J. Validation of a cervical dystonia questionnaire (CDQ). Mov Disord. 2010;25 Suppl 2:S233. [View poster]
18. Giovanni M, Hunter C, Ferrara J, Ondo WG. Predictors of initial adverse events in subjects receiving intermittent apomorphine injections. Mov Disord. 2010;25 Suppl 2:S296. [View poster]
19. Hunter CB, York MK, Jankovic J. Validation of a motor screen for undiagnosed parkinsonism: The Baylor Functional Assessment Screen (BFAS). Mov Disord. 2010;25 Suppl 2:S349. [View poster]
20. Palao AM, Mostile G, Hunter CB, Jankovic J. Assessing patients' access to tetrabenazine (xenazine) after FDA approval. Mov Disord. 2010;25 Suppl 2:S275. [View poster]
21. Ferrara J, Mostile G, Hunter C, Adam O, Jankovic J. Effect of tetrabenazine (TBZ) on motor function in patients with Huntington disease (HD). Neurology. 2010;74(9 Suppl 2):A412. [View poster]
22. Hunter CB, Aguilar LG, Nashatizadeh MM, Lay LF, Jankovic J. Evaluation of a Parkinson's disease screening questionnaire for use in a community-based setting. Mov Disord. 2008;23 Suppl 1:S361. [View poster]
23. Ondo WG, Hunter CB, Davidson A, Isaacson SH, Silver DE, Stewart RM, et al. Tolerability and efficacy of switching from swallowed selegiline to zydis selegiline (Zelapar®) in patients with Parkinson's disease. Mov Disord. 2008;23 Suppl 1:S222. [View poster]
24. Jimenez-Shahed J, Hunter CB, Jankovic J. Acamprosate improves impulse control disorders in Parkinson's disease. Neurology. 2008;70(11 Suppl 1):A288. [View poster]
25. Hunter CB, Tan EK, Lee J, Shinawi LM, Fook-Chong S, Jankovic J. Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population. Mov Disord. 2006;21 Suppl 15:S411-2. [View poster]
26. Kenney C, Diamond AL, Mejia N, Hunter CB, Jankovic J. Clinical features that distinguish psychogenic and essential tremor. Mov Disord. 2006;21 Suppl 15:S706. [View poster]
27. Kenney C, Hunter CB, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington disease. Mov Disord. 2006;21 Suppl 15:S635. [Previously Presented] [View poster]
28. Deng H, Le W, Guo Y, Hunter CB, Xie W, Huang M, et al. Examination of LRRK2 I2012T, G2019S, and I2020T mutations in patients with essential tremor. Ann Neurol. 2006;60 Suppl 10:S74.
29. Deng H, Le W, Hunter CB, Xie W, Mejia N, Jankovic J. A Mexican pedigree with Parkinson's disease, essential tremor and bell's palsy associated with parkin but not HS1BP3 gene mutation. Ann Neurol. 2006;60 Suppl 10:S58.
30. Hunter CB, Kenney K, Mejia N, Davidson A, Jankovic J. Medications associated with the onset of tardive dyskinesia. Ann Neurol. 2006;60 Suppl 10:S76. [View poster]
31. Kenney C, Hunter CB, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington disease. Ann Neurol. 2006;60 Suppl 10:S78. [View poster]
32. Kenney C, Simpson Jr RK, Hunter CB, Ondo WG, Almaguer M, Davidson A, et al. Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. Neurology. 2006;66(5 Suppl 2):A49-50. [View poster]
33. Kenney CJ, Vuong K, Hunter C, Almaguer M, Jankovic J. Long term safety of deep brain stimulation for the treatment of Parkinson's disease. Neurology. 2006;66(5 Suppl 2):A49-50.
34. Jankovic J, Hunter CB, the BOS Study Group. Botulinum toxin type B Observational Study (BOS). Ann Neurol. 2005;58 Suppl 9:S54.
35. Hunter C, Vuong KD, Mejia N, Jankovic J. Tetrabenazine: Does prior history of depression preclude this drug as a treatment option? Mov Disord. 2005;20 Suppl 10:S47. [View poster]
36. Jankovic J, Hunter C, Atassi MZ, Dolimbek BZ, Dolimbek GS, and BOS Research Group. Botulinum toxin type B Observational Study (BOS). Mov Disord. 2005;20 Suppl 10:S31. [View poster]
37. Mejia N, Vuong KD, Hunter C, Jankovic J. Medications associated with the onset of tardive dyskinesia.

Mov Disord. 2005;20 Suppl 10:S18. [View poster]

38. Mejia NI, Hunter C, Flores K, Ondo WG. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Mov Disord. 2005;20 Suppl 10:S10-1. [View poster]
39. Jankovic J, Hunter CB, Vuong KD . Safety and efficacy of tetrabenazine in the treatment of Huntington's disease and other choreas. Mov Disord. 2004;19(9):1127. [View poster]
40. Hunter C, Vuong KD, Mejia N, Jankovic J . Tetrabenazine, a monoamine depleter, effective in the treatment of Tourette syndrome. Mov Disord. 2004;19 Suppl 9:S437. [View poster]
41. Jankovic J, Hunter C, Mejia N, Vuong KD. Tetrabenazine: Effective treatment for tardive dyskinesia. Mov Disord. 2004;19 Suppl 9:S73. [View poster]
42. Vuong KD, Hunter C, Mejia N, Jankovic J. Safety and efficacy of tetrabenazine in childhood hyperkinetic movement disorders. Mov Disord. 2004;19 Suppl 9:S422. [View poster]
43. Hunter CB, Vuong KD, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Neurology. 2004;62(7 Suppl S5):A506-7. [View poster]
44. Jankovic J, Hunter CB, Vuong KD . Tetrabenazine in the treatment of chorea. Presented at the American Society for Experimental NeuroTherapeutics (ASENT), 6th Annual Meeting in Bethesda, Md. (March 11-13, 2004) [View poster]
45. Ondo WG, Hunter CB, Moore W . A double blind placebo controlled parallel trial of botulinum toxin B (Myobloc™) for the treatment of sialorrhea in parkinson disease. Neurology. 2003;60(5 Suppl 1):A47-8. [View poster]
46. Hunter CB, Wang A, Vuong KD, Jankovic J . Age-related tolerability of tetrabenazine. Mov Disord. 2002;17 Suppl 5:S41. [View poster]
47. Hunter CB, Wang A, Vuong KD, Jankovic J . Tetrabenazine in the treatment of Tourette syndrome. Mov Disord. 2002;17 Suppl 5:S341. [View poster]
48. Pan TH, Xu PY, Xie WJ, Hunter C, Jankovic J, Le WD. Upregulation of Nurr1 gene expression by dopamine receptor agonist pramipexole in human neuroblastoma SHSY-5Y cells. Mov Disord. 2002;17 Suppl 5:S84.
49. Ondo WG, Hunter C, Vuong KD, Jankovic J. Olanzapine treatment for dopaminergic induced hallucinations. Presented at the Movement Disorder Society (MDS), 6th International Congress of Parkinson's Disease and Movement Disorders in Barcelona, Spain (June 11-15, 2000).